INS and type 1 diabetes mellitus: Then, in stage two, they receive alemtuzumab, anakinra, etanercept and liraglutide to deplete T-cells, mitigate the anti-inflammatory response and stimulate ß-cell regeneration; this is being tested in patients with new-onset T1D to assess whether this will preserve endogenous islet cell function and insulin secretion [42].